Logo

American Heart Association

  2
  0


Final ID: MDP682

The Relationship Between Obesity Status and Change in NT-proBNP with Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Recent Worsening Heart Failure Event: Results from the PARAGLIDE-HF Trial

Abstract Body (Do not enter title and authors here): Background: In PARAGLIDE-HF, patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) and a recent worsening HF event randomized to sacubitril/valsartan (sac/val) vs val had a significantly larger reduction in NT-proBNP and were numerically more likely to derive clinical benefit as assessed by a win ratio. Patients with obesity and HFpEF may represent a unique phenotype, characterized by a high risk for recurrent HF hospitalization and lower levels of NT-proBNP.

Research Question: Does BMI category modify the relationship between sac/val vs val on NT-proBNP change and/or a win ratio among patients with HFpEF or mildly reduced EF?

Methods: To assess the interaction between BMI and sac/val vs val on NT-proBNP, the time-averaged proportional change in NT-proBNP from baseline to Weeks 4 and 8 was assessed with an analysis of covariance model including the interaction of treatment-by-BMI group (obese with BMI ≥30 vs normal/overweight, BMI 18.5 to <30 kg/m2). A win ratio of cardiovascular death, total HF hospitalizations, urgent HF visits, and change in NT-proBNP was calculated for both BMI groups, including an interaction term with significance set at ≤0.1.

Results: Overall, 65% (n=298) of patients had obesity and 35% (n=164) of patients had normal/overweight. When the interaction between BMI category and the effect of sac/val vs val on the time-averaged proportional change from baseline NT-proBNP was assessed, patients with obesity had a non-significant but numerically larger decrease in NT-proBNP (Table). Patients with obesity were also more likely to derive clinical benefit overall from sac/val vs val as compared to patients with normal/overweight (win ratio 1.38, 95% CI 1.01-1.90 vs 0.90, 95% CI 0.62-1.32, p interaction = 0.09).

Conclusion: These preliminary data suggest that patients with HF with mildly reduced or preserved EF and obesity may experience a larger clinical benefit from sac/val than patients with normal/overweight BMI.
  • Harrington, Josephine  ( Duke University , Chapel Hill , North Carolina , United States )
  • Ward, Jonathan  ( Novartis Pharmaceuticals , Portland , Oregon , United States )
  • Williamson, Kristin  ( Novartis Pharmaceuticals , Portland , Oregon , United States )
  • Zieroth, Shelley  ( University of Manitoba , Manitoba , Manitoba , Canada )
  • Sharma, Kavita  ( Johns Hopkins University SOM , Baltimore , Maryland , United States )
  • Mentz, Robert  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Adams, Kirkwood  ( University of North Carolina Chapel Hill , Chapel Hill , North Carolina , United States )
  • Hernandez, Adrian  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Lala, Anuradha  ( Mount Sinai Hospital , New York , New York , United States )
  • Peikert, Alexander  ( University of Graz , Graz , Austria )
  • Solomon, Scott  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Starling, Randall  ( Cleveland Clinic , Chagrin Falls , Ohio , United States )
  • Velazquez, Eric  ( Yale University School of Medicine , New Haven , Connecticut , United States )
  • Author Disclosures:
    Josephine Harrington: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) | Jonathan Ward: DO have relevant financial relationships ; Employee:Novartis Pharmaceuticals Corp:Active (exists now) ; Individual Stocks/Stock Options:Novartis Pharmaceuticals Corp:Active (exists now) | Kristin Williamson: DO have relevant financial relationships ; Employee:Novartis Pharmaceuticals, Corp:Past (completed) | Shelley Zieroth: DO have relevant financial relationships ; Consultant:Novartis:Past (completed) | Kavita Sharma: DO have relevant financial relationships ; Consultant:Alleviant:Active (exists now) ; Consultant:Eli Lily:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Edwards LifeSciences:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Bayer:Active (exists now) | Robert Mentz: DO have relevant financial relationships ; Researcher:AstraZeneca:Active (exists now) ; Researcher:American Regent:Active (exists now) ; Researcher:Bayer/Merck:Active (exists now) ; Researcher:BI/Lilly:Active (exists now) ; Researcher:Novartis:Active (exists now) | Kirkwood Adams: No Answer | Adrian Hernandez: DO have relevant financial relationships ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Verve:Active (exists now) ; Researcher:Intellia:Active (exists now) ; Researcher:NovoNordisk:Active (exists now) ; Researcher:Merck:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Cytokinetics:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Researcher:Boehringer Ingelheim:Active (exists now) ; Researcher:Bayer:Active (exists now) | Anuradha Lala: DO have relevant financial relationships ; Research Funding (PI or named investigator):Astra Zeneca:Active (exists now) ; Executive Role:Journal of cardiac failure:Active (exists now) ; Speaker:Novartts:Past (completed) ; Speaker:zoll:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):cytokinetics:Active (exists now) ; Consultant:Boehringer Ingelheim:Past (completed) ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Alexander Peikert: DO NOT have relevant financial relationships | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now) | Randall Starling: DO NOT have relevant financial relationships | Eric Velazquez: DO have relevant financial relationships ; Consultant:REDVIA Ltd:Active (exists now) ; Consultant:Baim:Active (exists now) ; Consultant:Novartis:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Cardiometabolic Conundrums in Heart Failure

Saturday, 11/16/2024 , 11:10AM - 12:25PM

Moderated Digital Poster Session

More abstracts on this topic:
A combined approach of cardiac magnetic resonance and CardioMEMS to assess right ventricular dysfunction during exercise in HFpEF-PH

Bekhuis Youri, Bogaert Jan, La Gerche Andre, Claessen Guido, Janssens Stefan, Droogne Walter, Rosseel Thomas, Barrios Leticia, Verwerft Jan, Timmermans Philippe, Trenson Sander, Dresselaers Tom

Amino acid and organic acid signature in urine of prepubescents with higher cardiometabolic risk evaluated by waist-to-height ratio

Oliveira Lilian Caroline, Azinheira Nobrega Cruz Nayara, Passadore Mariana, Bocato Mariana, Mill Jose Geraldo, Barbosa Jr Fernando, Casarini Dulce Elena

More abstracts from these authors:
Presentation

Cherney David, Petrie Mark, Zieroth Shelley, Kosiborod Mikhail

The Year in Heart Failure

Schiattarella Gabriele, Zieroth Shelley

You have to be authorized to contact abstract author. Please, Login
Not Available